home > drugs a-z list > multaq (dronedarone tablets) drug center > multaq (dronedarone tablets) drug - overdosage and contraindications

In the event of overdosage, monitor the patient's cardiac rhythm and blood pressure. Treatment should be supportive and based on symptoms.

It is not known whether dronedarone or its metabolites can be removed by dialysis (hemodialysis, peritoneal dialysis or hemofiltration). There is no specific antidote available.

MULTAQ (dronedarone tablets) is contraindicated in patients with:

• NYHA Class IV heart failure or NYHA Class II - III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic [see Boxed Warning and Clinical Studies]
• Second- or third-degree atrioventricular (AV) block or sick sinus syndrome (except when used in conjunction with a functioning pacemaker)
• Bradycardia < 50 bpm
• Concomitant use of strong CYP 3 A inhibitors, such as ketoconazole, itraconazole, voriconazole, cyclosporine, telithromycin, clarithromycin, nefazodone, and ritonavir [see DRUG INTERACTIONS]
• Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of Torsade de Pointes, such as phenothiazine anti-psychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics
• QTc Bazett interval ≥ 500 ms or PR interval > 280 ms
• Severe hepatic impairment
• Pregnancy (Category X): MULTAQ (dronedarone tablets) may cause fetal harm when administered to a pregnant woman. MULTAQ (dronedarone tablets) is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use In Specific Populations].
• Nursing mothers [see Use In Specific Populations]

Last reviewed on RxList: 5/10/2011
This monograph has been modified to include the generic and brand name in many instances.